GRCE
Grace Therapeutics, Inc.3.3400
+0.1000+3.09%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
51.68MP/E (TTM)
-Basic EPS (TTM)
-0.53Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
10-Q
Q2 FY2026 results
Grace Therapeutics narrowed its Q2 FY2026 operating loss to $2.5M from $4.8M y/y, while six-month loss shrank to $4.3M from $6.0M, driven by R&D spend dropping 81% to $0.6M after wrapping the GTx-104 Phase 3 STRIVE-ON trial. Cash burn eased to $4.9M (operating cash flow) for the half, leaving $16.9M in cash and equivalents at September 30, 2025—enough for 12+ months per management. Warrant liabilities swung positive by $1.4M on nearing expiration, trimming net loss to $0.9M ($0.06/share, anti-dilutive). FDA accepted the GTx-104 NDA in August 2025, PDUFA April 2026. Cash fuels pre-commercial push. Clinical trial delays loom large.
8-K
Q2 loss narrows; NDA advances
Grace Therapeutics reported Q2 2026 net loss of $0.9M, down from $3.4M year-over-year, as R&D expenses dropped $2.4M post-STRIVE-ON trial completion. FDA accepted GTx-104 NDA on August 22, 2025, with PDUFA target April 23, 2026; secured $4.0M from warrant exercises, boosting cash to $20.0M as of October 31. Cash runway extends to Q2 2027 if remaining warrants exercised. New patent strengthens IP to 2043.
ATXI
Avenue Therapeutics, Inc.
0.67+0.02
ATXS
Astria Therapeutics, Inc.
12.87-0.05
EPRX
Eupraxia Pharmaceuticals Inc.
6.25+0.09
FBRX
Forte Biosciences, Inc.
23.27+1.31
GANX
Gain Therapeutics, Inc.
3.86-0.09
GRI
GRI Bio, Inc.
0.48+0.00
GRTX
Galera Therapeutics, Inc.
0.02+0.00
OSTX
OS Therapies Incorporated
1.62-0.05
QNCX
Quince Therapeutics, Inc.
3.70-0.07
TECX
Tectonic Therapeutic, Inc.
18.69+0.30